Truscreen Group Ltd. · NZX:TRU
Truscreen — Shareholder Meeting (August 2023)
31 slides from Truscreen's shareholder meeting presentation, Aug 29, 2023
Slide 1: TruScreen Group Ltd
For personal use only TruScreen Group Ltd
Slide 2: This Presentation
2 This Presentation For personal use only ⚫ About TruScreen technology ⚫ WHO Strategy to eliminate CC, status ⚫ Key achievements in financial year 2023 ⚫ China, our biggest market ⚫ Sales growth in financial year 2023 ⚫ Outlook and goals for financial year 2024 ⚫ Key takeaways
Slide 3: About TruScreen technology
For personal use only About TruScreen technology
Slide 4: World class technology made simple
For personal use only truscreen’ WORLD CLASS technology made simple Real-time, Al-enabled, primary cervical cancer screening device for detection of pre-cancerous and cancerous cervical tissue Handheld Device > Optical and electrical measurements painlessly detect abnormalities in cervical tissue >
Slide 5: Cervical cancer
5 ► For personal use only ► ► 1 Cervical cancer (who.int)
Slide 6: Status of the WHO strategy, APEC
6 Status of the WHO strategy, APEC For personal use only 1 APEC Economic Status Report: Cervical Elimination in the APAC region, March 2023
Slide 7: Current markets and registrations
For personal use only 7 CE European Union: Europe 6.7 M 13.4 M CE Mark China ISO 13485 119.1 119.1 M 119.1 M M Registered with: Saudi 3.6 M ✓ TGA, Australia Mexico Vietnam ✓ MHRA, UK 10.7 M 8.3 M ✓ NMPA, China ✓ SFDA, Saudi Arabia India Indonesia ✓ Roszdravnadzor, Russia 100.1 M 23.1 M ✓ COFEPRIS, M
Slide 8: Effective co-invest model with global distribution
Effective co-invest model with global distribution ✓ ✓ For personal use only ✓ ✓ ✓ ✓ ➢ ➢ ➢ ➢ 8
Slide 9: Trusted Clinical Performance
9 Trusted Clinical Performance For personal use only 9
Slide 10: Key achievements Sales growth FY2023
Key For personal use only achievements Sales growth FY2023
Slide 11: Top Achievements FY23, China
11 Top Achievements FY23, China • For personal use only • • • ➢ ➢
Slide 12: China
China TruScreen’s largest market with growing sales and huge potential For personal use only ● ● ● ● ● ●
Slide 13: China Cervical Cancer Screening Market
13 China market, USD M, PBI Market Research 2020 For personal use only China Cervical Cancer Screening Market Historical and CAGR (USD Million), By Test Type, Forecast, USD Million* 2015 – 2026* 4000.0 16.0% 3500.0 14.0% 3000.0 12.0% 2500.0 10.0% 8.0% 2000.0 6.0% 1500.0 4.0% 1000.0 2.0% 500.0 0.0% 0
Slide 14: China and APAC market, recent growth exceeded expectations
14 China and APAC market, recent growth exceeded expectations For personal use only Business Market Insights June 2023: ➢ The Asia Pacific CIN & HR-HPV treatment market is expected to grow from US$ 2,738.94 million in 2023 to US$ 3,949.99 million by 2028. ➢ It is estimated to grow at a CAGR of 7.6%
Slide 15: China, the status and near future
15 China, the status and near future For personal use only In addition, we have a pipeline of: We currently have installed: • 14 Hospital tenders won and awaiting • More than 100 devices installation • 26 Hospitals which have approved TruScreen • Deployed in hospitals and awaiting tender clinics in
Slide 16: China, potential for SUS pull through growth
16 China, potential for SUS pull through growth For personal use only The devices in China ⚫currently have an average pull through of 85 SUS per device per month ⚫the potential average pull-through of SUS exceeds 290 per month ⚫Key accounts reach 500+ SUS pull through
Slide 17: Vietnam
Vietnam Focus market with renewed focus on public hospital rollout For personal use only ● ● ● ● ● ● ● ● *©2020 Precision Business Insights
Slide 18: FY23, Other Focus Markets
FY23,Other Focus Markets For personal use only ● ● ● ● ● ● ● ● ●
Slide 19: Top achievements FY2023
19 Top achievements FY2023 For personal use only ✓ ✓ ✓ ✓ ✓ ✓
Slide 20: Key Financials
For personal use only 20 KEY FINANCIALS FY 21 FY 22 FY 23 NZD (m) Actual Actual Actual ⚫ Sales 1.1 1.7 1.7 Total Revenue 2 2.7 2.2 COGS 0.7 1.3 1.3 R&D 1.3 1.5 0.9 ⚫ EBITDA -2.8 -2.7 Write off of Non-Current Assets - -4.6 -0.05 Amortisation & Depreciation -0.6 -0.6 - LOSS FOR YEAR -3.4 -7.9 -2.4 Net
Slide 21: Outlook strategy and goals FY2024-2025
Outlook strategy For personal use only and goals FY2024-2025
Slide 22: FY2024-FY2025 Strategy
For personal use only 22 FY2024- FY2025 Strategy Focus on 3 strategic drivers oe | Improve Strengthen operations partnerships + Enhance marketing + Enhance relationships + Reduce cost of goods * Talk economics (COGS) + Provide solutions Strong together Drive Growth * Double down on performance + Div
Slide 23: Our Short Term Goals
23 Our Short Term Goals For personal use only Maximise Expand Grow Improve Seize the CSCCP Successfully expand Grow commercial Improve the gross national guideline markets in presence in Africa, margin by reducing window to grow Zimbabwe, Saudi Middle East, Central COGS sales in China Arabia, and Vi
Slide 24: Long Term Goals
24 Expansion and adoption of For personal use only technology in the screening cervical cancer guidelines in target markets Long Term Goals Development of technology toward diagnostics and treatment of cervical cancer
Slide 25: Device installations and SUS pull-through
25 Device installations and SUS pull-through FY2019- FY2023 actual FY2024- FY2025 projections* For personal use only 450 300000 400 we are here 250000 350 300 200000 250 150000 200 150 100000 100 50000 50 0 0 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24* Mar '25* Installed Devices SUS Consumption
Slide 26: Key take-aways
Key take-aways ✓ Global growth For personal use only ✓ China remains the biggest market with huge opportunity ✓ Technology of the immediate future ✓ Growing and recognised medical need with strong clinical backing
Slide 27: Thank you!
For personal use only Thank you! 27
Slide 28: www.truscreen.com
For personal use only www.truscreen.com ©
Slide 29: For personal use only
For personal use only 29 @TruscreenGroupLtd @TruscreenGroupLimited
Slide 30: Disclaimers
ersonal use only jos . jo} LL 30 Disclaimers truscreen This presentation has been prepared by TruScreen Group Limited (the “Company") and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation.
Slide 31: References
For personal use only 31 References N w & uw a ™ t, 1 November 2020, bttps://www who int/news-room/fact- WHO, HPV and Cervical Cance Fei Chen, Guonan Zhang, Qing Yang, Manhua Cui, Yu Zhang, Renfeng Zhao, Weidong Zhao, Jiahua Liu, Xuejun Chen, Jinghe Lang. Evaluation of the effectiveness of an Al pow